203 related articles for article (PubMed ID: 37006288)
1. Characterization of heterogeneous metabolism in hepatocellular carcinoma identifies new therapeutic target and treatment strategy.
Yang J; Zeng L; Chen R; Zheng S; Zhou Y; Chen R
Front Immunol; 2023; 14():1076587. PubMed ID: 37006288
[TBL] [Abstract][Full Text] [Related]
2. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.
Liu Z; Zhang Y; Shi C; Zhou X; Xu K; Jiao D; Sun Z; Han X
J Transl Med; 2021 Jan; 19(1):5. PubMed ID: 33407585
[TBL] [Abstract][Full Text] [Related]
3. Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response.
Wu R; Gao Y; Zhao X; Guo S; Zhou H; Zhang Y; Hou Y; Mei L; Zhi H; Wang P; Li X; Ning S; Zhang Y
Comput Biol Med; 2023 Dec; 167():107593. PubMed ID: 37883849
[TBL] [Abstract][Full Text] [Related]
4. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
5. CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma.
Liu L; Liu Z; Gao J; Liu X; Weng S; Guo C; Hu B; Wang Z; Zhang J; Shi J; Guo W; Zhang S
Front Immunol; 2022; 13():964190. PubMed ID: 35967384
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive molecular and immunological characterization of hepatocellular carcinoma.
Shimada S; Mogushi K; Akiyama Y; Furuyama T; Watanabe S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Arii S; Tanabe M; Wands JR; Tanaka S
EBioMedicine; 2019 Feb; 40():457-470. PubMed ID: 30598371
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma.
Weng J; Liu S; Zhou Q; Xu W; Xu M; Gao D; Shen Y; Yi Y; Shi Y; Dong Q; Zhou C; Ren N
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37385725
[TBL] [Abstract][Full Text] [Related]
8. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
9. Identification of molecular heterogeneity of hepatocellular carcinoma based on immune gene expression signatures.
Lou X; Wang JJ; Wei YQ; He YJ; Jiang ZJ; Sun JJ
Med Oncol; 2021 Mar; 38(5):50. PubMed ID: 33786682
[TBL] [Abstract][Full Text] [Related]
10. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes.
Bidkhori G; Benfeitas R; Klevstig M; Zhang C; Nielsen J; Uhlen M; Boren J; Mardinoglu A
Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11874-E11883. PubMed ID: 30482855
[TBL] [Abstract][Full Text] [Related]
11. Single-Cell Sequencing Identifies the Heterogeneity of CD8+ T Cells and Novel Biomarker Genes in Hepatocellular Carcinoma.
Wang H; Fu Y; Da BB; Xiong G
J Healthc Eng; 2022; 2022():8256314. PubMed ID: 35449866
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
[TBL] [Abstract][Full Text] [Related]
13. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma.
Huo J; Cai J; Wu L
Cancer Med; 2023 Jan; 12(1):898-912. PubMed ID: 35651292
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma.
Huo J; Wu L; Zang Y
J Cell Mol Med; 2021 Jan; 25(2):1151-1165. PubMed ID: 33300278
[TBL] [Abstract][Full Text] [Related]
17. Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma.
Xu W; Nie C; Lv H; Chen B; Wang J; Wang S; Zhao J; He Y; Chen X
Front Immunol; 2022; 13():1010554. PubMed ID: 36275697
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets.
Agarwal R; Narayan J; Bhattacharyya A; Saraswat M; Tomar AK
Cancer Genet; 2017 Oct; 216-217():37-51. PubMed ID: 29025594
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
20. Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy.
Wang Y; Peng B; Ning C; He S; Yang H; Mao Y; Sun L
Front Immunol; 2022; 13():966167. PubMed ID: 36304466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
